

9 April 2014

**INVION MD & CEO, DR GREG COLLIER,
PRESENTS AT THE 11th ANNUAL BIO ASIA INTERNATIONAL CONFERENCE**

Australian drug development company Invion Limited (ASX: IVX) is pleased to announce that Managing Director and Chief Executive Officer, Dr Greg Collier, will be presenting at the the BIO Asia International Conference, in Tokyo, Japan.

BIO Asia is an exclusive, customized partnering forum that brings together drug development companies with Asian biotech and pharmaceutical companies interested in research collaborations and licensing agreements.

Dr Collier's presentation will highlight:

- Invion's growing pipeline of assets under development in the fields of respiratory and inflammation;
- The development strategy underpinning the respiratory drug franchise, including the recent collaboration with 3M Drug Delivery Systems to develop inhaled versions of Invion's two respiratory drug assets INV102(nadolol) and INV104 (zafirlukast); and
- The development of INV103 (ala-Cpn10) including its positioning as a founding member of the Resolution Associated Molecular Pattern (RAMPs) family - a critical component of prevention of autoimmunity.

Date: 9 April 2014

Location: Grand Hyatt, Tokyo

Web: <http://www.bio.org/events/conferences/11th-annual-bio-asia-international-conference>

About Invion Limited

Invion is a life sciences company focussed on the development of treatments for major opportunities in respiratory disease and autoimmune disease. The Group has three drug assets in development, and three phase II clinical trials, regulated by the Food & Drug Administration (FDA), currently underway in the United States. INV102 (nadolol) a beta blocker (beta adrenergic inverse agonist) currently used to treat high blood pressure and migraine, is being repurposed to treat chronic inflammatory airway diseases, including asthma and chronic obstructive pulmonary disease (COPD). INV104 (zafirlukast) is a leukotriene receptor antagonist (LTRA) that reduces inflammation, constriction of the airways, and the build-up of mucus in the lungs. INV103 (ala-Cpn10) is a modified, naturally occurring human protein which has been proposed as a founding member of the Resolution Associated Molecular Pattern (RAMPs) family hypothesised to maintain and restore immune homeostasis. Invion is an ASX listed company (ASX:IVX), with its clinical headquarters in Delaware, USA.

FOR MORE INFORMATION CONTACT

Managing Director and CEO: Dr Greg Collier. P: 07 3295 0506 investor@inviongroup.com